ERBB RECEPTOR INHIBITORS Russian patent published in 2023 - IPC C07D409/12 C07D401/14 C07D403/14 C07D471/04 A61K31/517 A61P35/00 A61P35/04 

FIELD: pharmaceuticals.

SUBSTANCE: group of inventions relates to a compound of Formula (I)

,

or a pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof, also relates to a pharmaceutical composition for inhibiting HER2 containing an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof, also relates to a method of inhibiting HER2 comprising the use of a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof, also relates to a method of treating a HER2-associated disease in a subject, comprising administering to said subject an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate thereof, solvate or stereoisomer, also refers to a pharmaceutical combination having inhibitory activity against HER2, which contains a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof, also refers to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, hydrate, solvate, or stereoisomer in the manufacture of a medicament for treating a HER2-associated disease in a subject.

EFFECT: group of inventions ensures the development of compounds of Formula (I) as HER2 inhibitors.

26 cl, 3 tbl, 31 ex